Search Results - "RICCARDI, F."

Debonding Analysis of Fibre Reinforced Polymer Anchors in Concrete via In-Situ X-Ray Microtomography Tests Coupled to Volume and Digital Image Correlation by Riccardi, F., Giry, C., Gatuingt, F.

“…Background Externally Bonded (EB) Fibre Reinforced Polymer (FRP) strengthening systems are effective solutions for enhancing structural members’ flexural…”
Get full text

Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients by Trevisan, B., Pepe, F. F., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Clivio, L., Torri, V., Cazzaniga, M. E.

“…Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and…”
Get full text

Genetics of neonatal onset epilepsies: An overview by Milh, M., Riccardi, F., Denis, J.

“…The weight of monogenic abnormalities in the possible causes of epilepsy has grown significantly in recent years, due to the emergence of next-generation…”
Get full text

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study by Cazzaniga, M.E., Pinotti, G., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Fiorentini, G., Fontana, A., Gambaro, A.R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Melegari, E., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M.G., Schintu, M.G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M.R., Vici, P., Clivio, L., Torri, V., Cicchiello, F., Riva, F., Vallini, I., Mazza, M., Bonfadini, C., Bordin, E., Canicattì, M., Cappuccio, F., Collovà, E., De Angelis, C., Desorte, R., Donati, S., Drudi, G., Galanti, D., Mocerino, C., Orlando, L., Pellegrino, B., Pizzuti, L., Ridolfi, C., Rocca, A., Sarti, D., Spagnoletti, I., Tinari, N., Vandone, A., Vizzini, L.

“…Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no…”
Get full text

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study by Cazzaniga, M. E., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Di Mauro, P., Cogliati, V., Capici, S., Clivio, L., Torri, V.

“…Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor…”
Get full text

Production of innovative radionuclides for medical applications at the CERN-MEDICIS facility by Bernerd, C., Johnson, J.D., Aubert, E., Au, M., Barozier, V., Bernardes, A.-P., Bertreix, P., Bruchertseifer, F., Catherall, R., Chevallay, E., Chrysalidis, K., Christodoulou, P., Cocolios, T.E., Crepieux, B., Deschamps, M., Dorsival, A., Duchemin, C., Fedosseev, V., Fernier, P., Heines, M., Heinke, R., Khalid, U., Khan, M., Khan, Q., Lambert, L., Mamis, E., Marsh, B.A., Marzari, S., Menaa, N., Munos, M., Pozzi, F., Prvakova, S., Ramos, J.P., Riccardi, F., Rinchet, J.-Y., Rossel, R.E., Stora, T., Thiboud, J., Vollaire, J., Van Den Bergh, V., Wojtaczka, W.

“…Since its commissioning in December 2017, the CERN-MEDICIS facility has been providing non-conventional radionuclides for research in nuclear medicine…”
Get full text

Multiple venous malformations revealing a familial cerebral cavernomatosis by Benzaquen, M., Fareau, J., Riccardi, F., Philip‐Sarles, N., Bertrand, F., Berbis, P., Delaporte, E.

Get full text

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial by Perrone, F., Nuzzo, F., Di Rella, F., Gravina, A., Iodice, G., Labonia, V., Landi, G., Pacilio, C., Rossi, E., De Laurentiis, M., D'Aiuto, M., Botti, G., Forestieri, V., Lauria, R., De Placido, S., Tinessa, V., Daniele, B., Gori, S., Colantuoni, G., Barni, S., Riccardi, F., De Maio, E., Montanino, A., Morabito, A., Daniele, G., Di Maio, M., Piccirillo, M.C., Signoriello, S., Gallo, C., de Matteis, A.

“…Evidence on adjuvant chemotherapy for elderly early breast cancer patients is poor, due to the low number of phase 3 trials. ELDA shows that weekly docetaxel…”
Get full text

Phase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL) by Gelsomino, F., Tiseo, M., Barbieri, F., Riccardi, F., Cavanna, L., Frassoldati, A., Delmonte, A., Longo, L., Dazzi, C., Cinieri, S., Colantonio, I., Tognetto, M., Baldari, D., Tofani, L., Ardizzoni, A.

Get full text

The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid by Perrone, F., De Laurentiis, M., de Placido, S., Orditura, M., Cinieri, S., Riccardi, F., Ribecco, A.S., Putzu, C., Del Mastro, L., Rossi, E., Daniele, B., Mosconi, A.M., Di Rella, F., Landi, G., Nuzzo, F., Pacilio, C., Lauria, R., Arenare, L., Piccirillo, M.C., Gallo, C.

Get full text

Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study by Pronzato, P, Mustacchi, G, Riccardi, F, Turletti, A, Michelotti, A, Natoli, C, Livi, L, Del Mastro, L, Donadio, M, Garrone, O, Giordano, M, De Laurentiis, M, Marchetti, P, Montemurro, F, Romagnoli, E, De Placido, S, Biganzoli, L, Cazzaniga, M

Get full text

Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study by Mustacchi, G, Cazzaniga, M, Giordano, M, Garrone, O, Donadio, M, Del Mastro, L, Livi, L, Natoli, C, Michelotti, A, Turletti, A, Riccardi, F, Marchetti, P, Montemurro, F, Romagnoli, E, De Placido, S, Biganzoli, L, Bisagni, G, Bria, E

Get full text

The natural history of mild haemophilia: a 30-year single centre experience by TAGLIAFERRI, A., DI PERNA, C., RICCARDI, F., PATTACINI, C., RIVOLTA, G. F., FRANCHINI, M.

“…Although up to 50% of all haemophilic patients followed at haemophilia treatment centres (HTCs) are affected by a mild factor VIII (FVIII) or factor IX (FIX)…”
Get full text

A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer by Conte, B, Poggio, F, Guarneri, V, Rota Caremoli, E, Rocca, A, Montemurro, F, De Laurentiis, M, Garrone, O, Giordano, M, Bisagni, G, Riccardi, F, Amaducci, L, Ferzi, A, La Verde, N, Cognetti, F, Bighin, C, Cardinali, B, Pfeffer, U, Lambertini, M, Del Mastro, L

Get full text

Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial by De Placido, S., Gallo, C., De Laurentiis, M., Bisagni, G., Arpino, G., Sarobba, M.G., Riccardi, F., Russo, A., Del Mastro, L., Cogoni, A., Cognetti, F., Gori, S., Frassoldati, A., Amoroso, D., Laudadio, L., Moscetti, L., Montemurro, F., Nuzzo, F., Carlini, P., Perrone, F.

Get full text

The spectrum of factor XI deficiency in Italy by Castaman, G., Giacomelli, S. H., Caccia, S., Riccardi, F., Rossetti, G., Dragani, A., Giuffrida, A. C., Biasoli, C., Duga, S.

“…Summary Factor XI (FXI) deficiency is a rare inherited bleeding disorder invariably caused by mutations in the FXI gene. The disorder is rather frequent in…”
Get full text

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study by Schettini, F., Conte, B., Buono, G., De Placido, P., Parola, S., Griguolo, G., Fabi, A., Bighin, C., Riccardi, F., Cianniello, D., De Laurentiis, M., Puglisi, F., Pelizzari, G., Bonotto, M., Russo, S., Frassoldati, A., Pazzola, A., Montemurro, F., Lambertini, M., Guarneri, V., Cognetti, F., Locci, M., Generali, D., Conte, P., De Placido, S., Giuliano, M., Arpino, G., Del Mastro, L.

“…The current standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive (+) metastatic breast cancer is the combination of…”
Get full text

Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study by LORUSSO, V, GIOTTA, F, BORDONARO, R, MAIELLO, E, DEL PRETE, S, GEBBIA, V, FILIPELLI, G, PISCONTI, S, CINIERI, S, ROMITO, S, RICCARDI, F, FORCIGNANÒ, R, CICCARESE, M, PETRUCELLI, L, SARACINO, V, LUPO, L.I, GAMBINO, A, LEO, S, COLUCCI, G

“…We conducted a phase III multicenter randomized trial to compare the efficacy of the combination of liposome encapsulated doxorubicin (Myocet©) plus either…”
Get full text

The therapy of kidney cancer with biomolecular drugs by Di Lorenzo, G, Buonerba, C, Biglietto, M, Scognamiglio, F, Chiurazzi, B, Riccardi, F, Cartenì, G

“…SUMMARY Purpose Over the last few years, targeted agents have assumed a predominant role in treatment of metastatic renal cell carcinoma (mRCC). Our aim is to…”
Get full text

Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study by Gobbini, E., Chiari, R., Pizzutillo, P., Bordi, P., Ghilardi, L., Pilotto, S., Osman, G., Cappuzzo, F., Cecere, F., Riccardi, F., Scotti, V., Martelli, O., Borra, G., Maiello, E., Rossi, A., Graziano, P., Gregorc, V., Casartelli, C., Sergi, C., Del Conte, A., Delmonte, A., Bareggi, C., Cortinovis, D., Rizzo, P., Tabbò, F., Rossi, G., Bria, E., Galetta, D., Tiseo, M., Di Maio, M., Novello, S.

“…Purpose Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several…”
Get full text